Search: onr:"swepub:oai:lup.lub.lu.se:2e786ed9-f17a-4b9a-947b-78ad201791cf" >
Mechanisms and ther...
Mechanisms and therapeutic prospects of thrombopoietin receptor agonists
-
- Bussel, James (author)
- Cornell University
-
- Kulasekararaj, Austin (author)
- King's College Hospital
-
- Cooper, Nichola (author)
- Hammersmith Hospital
-
show more...
-
- Verma, Amit (author)
- Yeshiva University
-
- Steidl, Ulrich (author)
- Yeshiva University
-
- Semple, John W. (author)
- Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Hematogenomics,Forskargrupper vid Lunds universitet,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Lund University Research Groups
-
- Will, Britta (author)
- Yeshiva University
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2019
- 2019
- English.
-
In: Seminars in Hematology. - : Elsevier BV. - 0037-1963. ; 56:4, s. 262-278
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- The second-generation thrombopoietin (TPO) receptor agonists eltrombopag and romiplostim are potent activators of megakaryopoiesis and represent a growing treatment option for patients with thrombocytopenic hematological disorders. Both TPO receptor agonists have been approved worldwide for the treatment of children and adults with chronic immune thrombocytopenia. In the EU and USA, eltrombopag is approved for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy and in the USA for the first-line treatment of severe aplastic anemia in combination with immunosuppressive therapy. Eltrombopag has also shown efficacy in several other disease settings, for example, chemotherapy-induced thrombocytopenia, selected inherited thrombocytopenias, and myelodysplastic syndromes. While both TPO receptor agonists stimulate TPO receptor signaling and enhance megakaryopoiesis, their vastly different biochemical structures bestow upon them markedly different molecular and functional properties. Here, we review and discuss results from preclinical and clinical studies on the functional and molecular mechanisms of action of this new class of drug.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Keyword
- Eltrombopag
- Mechanism of action
- Megakaryopoiesis
- Romiplostim
- Thrombocytopenia
Publication and Content Type
- for (subject category)
- ref (subject category)
Find in a library
To the university's database